Federal Circuit Rejects Biotech Company’s Rehearing Bid For DNA Patent Claims
WASHINGTON, D.C. — The Federal Circuit U.S. Court of Appeals rejected a gene therapy product maker’s petition for rehearing en banc, leaving in place a panel’s finding that a Delaware federal...To view the full article, register now.
Already a subscriber? Click here to view full article